373 related articles for article (PubMed ID: 32012118)
1. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
2. Significance of KDM6A mutation in bladder cancer immune escape.
Chen X; Lin X; Pang G; Deng J; Xie Q; Zhang Z
BMC Cancer; 2021 May; 21(1):635. PubMed ID: 34051747
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
4. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
5. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
[TBL] [Abstract][Full Text] [Related]
6. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
7. FLG Gene Mutation Up-regulates the Abnormal Tumor Immune Response and Promotes the Progression of Prostate Cancer.
Zhang P; An Z; Sun C; Xu Y; Zhang Z
Curr Pharm Biotechnol; 2022; 23(14):1658-1670. PubMed ID: 35422210
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis Reveals That
Chen Z; Chen C; Li L; Zhang T; Wang X
Front Cell Dev Biol; 2021; 9():729927. PubMed ID: 34616736
[No Abstract] [Full Text] [Related]
9. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
10. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
11.
Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
[TBL] [Abstract][Full Text] [Related]
12.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
14. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
Krupar R; Watermann C; Idel C; Ribbat-Idel J; Offermann A; Pasternack H; Kirfel J; Sikora AG; Perner S
Sci Rep; 2020 Jun; 10(1):9389. PubMed ID: 32523042
[TBL] [Abstract][Full Text] [Related]
15. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
16. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N; Liu J; Xu M; Liang J; Wang Y; Wu Z; Xing Y; Diao F
Int J Gen Med; 2021; 14():7647-7657. PubMed ID: 34764678
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients.
Liu B; Dong Z; Lu Y; Ma J; Ma Z; Wang H
Evid Based Complement Alternat Med; 2022; 2022():3478861. PubMed ID: 36034941
[TBL] [Abstract][Full Text] [Related]
18. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
Luo M; Zhang Y; Xu Z; Lv S; Wei Q; Dang Q
Mol Med; 2023 Jan; 29(1):7. PubMed ID: 36647005
[TBL] [Abstract][Full Text] [Related]
19. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Grivas P; Mortazavi A; Picus J; Hahn NM; Milowsky MI; Hart LL; Alva A; Bellmunt J; Pal SK; Bambury RM; O'Donnell PH; Gupta S; Guancial EA; Sonpavde GP; Faltaos D; Potvin D; Christensen JG; Chao RC; Rosenberg JE
Cancer; 2019 Feb; 125(4):533-540. PubMed ID: 30570744
[TBL] [Abstract][Full Text] [Related]
20. Association Analyses of
Wen XM; Xu ZJ; Jin Y; Xia PH; Ma JC; Qian W; Lin J; Qian J
Front Immunol; 2021; 12():717527. PubMed ID: 34745095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
